Merck to Present New Data for KEYTRUDA ® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
Dateline City: KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this year’s American Association for Cancer Research (AACR) Annual Meeting in New Orleans, April 16 – 20. Language: English Contact: Merck Media: Pam Eisele, 267-305-3558 Kim Hamilton, 908-740-1863 or Investor: Teri Loxam, 908-740-1986 Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
A new study finds that fecal hemoglobin can indicate more than an increased risk for colorectal cancer and is tied to an increased risk for all-cause mortality.Medscape Medical News
The F.D.A. announced that batches of a widely used generic drug, valsartan, made in China, might be tainted with a probable cancer-causing ingredient.
THE test for bowel cancer may also provide some insight into whether patients are at risk of other health problems, a study suggests. Detecting "hidden" blood in stool is a commonly used method for bowel cancer screening.
Newest Advances and Strategies in Prostate Cancer: Science and Stories on the Evolving Treatment Landscape and Implications for Patient Care
Germline BRCA mutations and other HR genes may offer biomarkers for response to this treatment.
The statement emphasizes strategies for multidisciplinary care, and proposes an algorithm for clinical management of bone metastasis in RCC.
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials, Published online: 17 July 2018; doi:10.1038/s41416-018-0165-zRelationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
MicroRNAs (miRNAs) have emerged as crucial regulators of T lymphocyte survival, differentiation and function, all of which are key factors impacting the outcome of adoptive T cell-based immunotherapy. It has become increasingly clear that the adoptive transfer of memory CD8+ T cell subsets is highly correlated with objective clinical responses for patients with advanced cancer. However, it is unclear how to improve the long-term persistence of transferred CD8+ T cells using miRNAs. Here, we highlight the current advances in our understanding of the role of miRNAs in regulating the differentiation of memory CD8+ T cells. We...
Conclusions: Circulating HDL is significantly associated with treatment outcomes in patients with locoregionally advanced NPC. We suggest that HDL measurements will be of great clinical significance in the management of NPC.Cell Physiol Biochem 2018;48:285 –292
Dr. John Kisiel, MD, Mayo Clinic, talks Setting Specificity and Sensitivity for Tests | Involves recruiting up to 500 At-Risk Control Patients for DDW 2018 Author: Cancer-News Added: 07/16/2018